

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 11/035, 377
Source: 1-14-05 IFWO
Date Processed by STIC: 2-2-05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 4.2.2 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 11/035,377

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 ☐ **Wrapped Nucleics
Wrapped Aminos** The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 ☐ **Invalid Line Length** The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 ☐ **Misaligned Amino
Numbering** The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 ☒ **Non-ASCII** The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 ☐ **Variable Length** Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 ☐ **PatentIn 2.0
"bug"** A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 ☐ **Skipped Sequences
(OLD RULES)** Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 ☐ **Skipped Sequences
(NEW RULES)** Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 9 ☐ **Use of n's or Xaa's
(NEW RULES)** Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 ☐ **Invalid <213>
Response** Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 ☐ **Use of <220>** Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 ☐ **PatentIn 2.0
"bug"** Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 ☐ **Misuse of n/Xaa** "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid

11/035, 377

This is a NON-ASCII text file, pls see item #4 on error summary sheet. Page 1

SEQUENCE LISTING

Invalid numeric identifier
Applicant info. is inserted at numeric identifier 1107

pls insert:
1407 current Application #
1417 current filing date
1607 # of Seq ID #s
1707 software type

<100> EP Hoffman et al. Dkt. No. 64688/157
<120> please insert title of invention
<130> insert here ← move to

<200> SEQUENCE CHARACTERISTICS delete

<210> SEQ ID NO.1 (-G171T) move to section 2207-2237

<211> 60

<212> DNA

<213> Homo sapiens

<313> Allele G/T This response is to be inserted into 2207-2237.

<400> 1

CCCAGGAGGT TTTTG[G/T]GCTT GCCTGGAGGG CCCAGGAGGT
TTTGGCTTG CGCTGGAGGG

<200> SEQUENCE CHARACTERISTICS delete

<210> SEQ ID NO.2 (-C8541T) move to section 2207-2237,

<211> 62

<212> DNA

<213> Homo sapiens

<313> Allele C/T Insert into section 2207-2237.

<400> 2

GCCAGACTT CAACGA[C/T]AGG TCCAGGGCCT.GG

GCCAGACT.TCAACGAAGG TCCAGGGCCT.GG

<200> SEQUENCE CHARACTERISTICS delete

<210> SEQ ID NO.3 (-C12273A) Insert into section 2207-2237.

<211> 61

<212> DNA

<213> Homo sapiens

<313> Allele C/T Insert into section 2207-2237.

<400> 3

GCCTGCAGGA CAGGG[C/T]ACTG GTCCAAACTC ACCCTGCAGG

ACAGGGACTG GTCCAAACTC A

pls do not use numeric identifiers

Invalid numeric identifier

EVI:
pls group nucleotides in sets of tens.
For example:
aatcgaaggt

The type of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.

Pls see the (Attached) sample sequence listing.

11/035, 377

Page 2

Certification

The undersigned certifies that the SEQUENCING LISTING shown above is exactly the same as that appearing in the paper patent application.

/Dr. Melvin Blecher/ 01/03/2004
Reg. No. 33,649
Attorney for Applicant

1 p/s delete

(Sample Sequence Listing)

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> .01-00001

<140> PCT/EP98/00001

<141> 1998-12-31

<150> US 08/999,999

<151> 1997-10-15

<160> 4

<170> PatentIn version 2.0

<210> 1

<211> 389

<212> DNA

<213> Paramecium sp.

<220>

<221> CDS

<222> (279)...(389)

<300>

<301> Doe, Richard

<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.

<303> Journal of Genes

<304> 1

<305> 4

<306> 1-7

<307> 1988-06-31

<308> 123456

<309> 1988-06-31

<400> 1

agctgtagtc	attcctgtgt	cctcttctct	ctgggcttct	cacctgcta	atcagatctc	60
agggagagtg	tcttgacct	cctctgcctt	tgcagcttca	caggcaggca	ggcaggcagc	120
tgatgtggca	attgctggca	gtgccacagg	cttttcagcc	aggcttaggg	tgggttcgc	180
cgcggcgcg	cggccctct	cgcgctctc	tcgcgctct	ctctcgctct	cctctcgctc	240

ggacctgatt	aggtgagcag	gaggagggggg	cagtttagc	atg Met 1	gtt Val	tca Ser	atg Met	ttc Phe 5	agc Ser	296						
ttg Leu	tct Ser	ttc Phe	aaa Lys 10	tgg Trp	cct Pro	gga Gly	ttt Phe	tgt Cys 15	ttg Leu	ttt Phe	gtt Val	tgt Cys	ttg Leu 20	ttc Phe	caa Gln	344
tgt Cys	ccc Pro	aaa Lys 25	gtc Val	ctc Leu	ccc Pro	tgt Cys	cac His 30	tca Ser	tca Ser	ctg Leu	cag Gln	ccg Pro 35	aat Asn	ctt Leu	389	

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2	Met 1	Val	Ser	Met	Phe 5	Ser	Leu	Ser	Phe	Lys 10	Trp	Pro	Gly	Phe	Cys 15	Leu
	Phe	Val	Cys	Leu 20	Phe	Gln	Cys	Pro	Lys 25	Val	Leu	Pro	Cys	His 30	Ser	Ser
	Leu	Gln	Pro 35	Asn	Leu											

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3	Met 1	Val	Asn	Leu	Glu 5	Pro	Met	His	Thr	Glu 10	Ile
---------	----------	-----	-----	-----	----------	-----	-----	-----	-----	-----------	-----

<210> 4
<400> 4
000

[Annex VIII follows]